Adding ipilimumab to pembrolizumab does not improve efficacy in patients with NSCLC
Research presented today at the International Association for the Study of Lung Cancer's World Conference on Lung Cancer
2021-01-30
(Press-News.org) (Singapore Embargoed for 7:23pm EST on January 29, 2021 to coincide with publication in the Journal of Clinical Oncology) -- Adding ipilimumab to pembrolizumab does not improve efficacy and is associated with greater toxicity than pembrolizumab alone as first-line therapy for metastatic non-small cell lung cancer (NSCLC) for patients with a PD-L1 tumor proportion score of greater than or equal to 50% and no targetable EGFR or ALK aberrations, according to research presented today at the International Association for the Study of Lung Cancer's World Conference on Lung Cancer.
The research was presented by Dr. Michael Boyer, clinical professor of medicine at the Chris O'Brien Lifehouse and the Central Clinical School of the University of Sydney, Sydney, Australia.
Previously, the KEYNOTE-024 study showed that pembrolizumab monotherapy significantly improved survival versus platinum-doublet chemotherapy for patients with metastatic NSCLC, a PD-L1 TPS greater than or equal to 50%, and no targetable EGFR or ALK aberrations.
Boyer and his research group, which consisted of centers in Europe, Asia, and North America, conducted the randomized, double-blind, phase III KEYNOTE-598 study (NCT03302234) to determine whether adding ipilimumab to pembrolizumab improved efficacy over pembrolizumab alone in this population.
The trial enrolled 568 participants -- 284 received a combination of pembrolizumab and ipilimumab and 284 were randomly assigned to receive pembrolizumab and placebo.
Patients were randomly assigned 1:1 to ipilimumab at 1 mg/kg every six weeks or to saline placebo for up to 18 cycles. Patients in both arms received 200 mg of pembrolizumab every three weeks for up to 35 cycles. Random assignment was stratified by European Cooperative Oncology Group score of (0 vs 1), region (East Asia vs not East Asia), and histology (squamous vs nonsquamous). Treatment differences in the primary endpoints of overall survival and progress-free survival were assessed by the stratified log-rank test in the intent-to-treat population.
The protocol-specified first interim analysis (IA1) was planned to occur when approximately 255 deaths occurred and approximately 12 months had passed since the last participant was randomly assigned. Nonbinding futility criteria at IA1 were differences in the restricted mean survival time between ipilimumab/pembrolizumab and placebo/pembrolizumab of less than or equal to 0.2 at the maximum observation time and less than or equal to 0.1 at 24 months of follow-up.
With 272 deaths, median overall survival was 21.4 months for patients who received ipilimumab/pembrolizumab compared to 21.9 months for placebo/pembrolizumab (HR, 1.08 ;95% CI: 0.85-1.37; p = 0.74). Restricted mean survival time differences were -0.56 at the maximum observation time and -0.52 at 24 months, which met the futility criteria, according to Dr. Boyer.
With 372 events, median progression-free survival was 8.2 months for the ipilimumab/pembrolizumab group compared with 8.4 months for placebo/pembrolizumab (HR, 1.06; 95% CI: 0.86-1.30; p = 0.72). The objective response rate was 45.4% in both arms; median duration of response was 16.1 months for the ipilimumab/pembrolizumab group vs 17.3 months for placebo/pembrolizumab. Treatment-related adverse events occurred in 76.2% of patients in the ipilimumab/pembrolizumab group versus 68.3% for the placebo group.
Dr. Boyer reported that based on the observed efficacy and safety, the external data monitoring committee recommended that the study be stopped due to futility and that participants discontinue both ipilimumab and placebo.
"As a consequence of the results of this study, monotherapy with pembrolizumab remains a standard of care for this population of patients. Despite the benefits of this type of treatment, almost 50% of these patients die of their disease within two years, so future research will focus on other ways to improve outcomes," he reported.
INFORMATION:
About the IASLC:
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 8,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. Visit http://www.iaslc.org for more information.
About the WCLC:
The WCLC is the world's largest meeting dedicated to lung cancer and other thoracic malignancies, attracting nearly 7,500 researchers, physicians and specialists from more than 100 countries. The goal is to increase awareness, collaboration and understanding of lung cancer, and to help participants implement the latest developments across the globe. The conference will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more information, visit wclc2020.iaslc.org.
ELSE PRESS RELEASES FROM THIS DATE:
2021-01-29
New research led by Carnegie Mellon University Assistant Professor of Physics Shiladitya Banerjee demonstrates how certain types of bacteria can adapt to long-term exposure to antibiotics by changing their shape. The work was published this month in the journal Nature Physics.
Adaptation is a fundamental biological process driving organisms to change their traits and behavior to better fit their environment, whether it be the famed diversity of finches observed by pioneering biologist Charles Darwin or the many varieties of bacteria that humans coexist with. While antibiotics have long helped people prevent and cure bacterial infections, many species of bacteria have increasingly been able to adapt to ...
2021-01-29
School closures during COVID-19 have decreased access to school meals, which is likely to increase the risk for food insecurity among children in Maryland, according to a new report issued by researchers at the University of Maryland School of Medicine (UMSOM). The number of meals served to school-age children during the first three months of the pandemic dropped by 58 percent, compared to the number of free or reduced-price meals served the previous spring. As a result, thousands of children across the state were placed at increased risk of food insecurity, with many likely experiencing the health ramifications ...
2021-01-29
Boulder, Colo., USA: GSA's dynamic online journal, Geosphere, posts articles online regularly. Topics for articles posted for Geosphere this month include feldspar recycling in Yosemite National Park; the Ragged Mountain Fault, Alaska; the Khao Khwang Fold and Thrust Belt, Thailand; the northern Sierra Nevada; and the Queen Charlotte Fault.
Feldspar recycling across magma mush bodies during the voluminous Half Dome and Cathedral Peak stages of the Tuolumne intrusive complex, Yosemite National Park, California, USA
Louis F. Oppenheim; Valbone Memeti; Calvin G. Barnes; Melissa Chambers; Joachim Krause ...
Abstract: Incremental pluton growth can produce sheeted complexes with no magma-magma interaction or large, dynamic magma bodies communicating via crystal and melt exchanges, depending ...
2021-01-29
Washington, DC — Blood pressure that remains elevated over of time — known as chronic hypertension — has been linked to heart disease, which is the leading cause of death in the United States. Recent research has shown that persistent high blood pressure may also increase the risk for stroke and overall mortality. Yet, only about 1 in 4 adults with chronic hypertension have their condition under control, according to the Centers for Disease Control and Prevention.
In a new study to be presented today at the Society for Maternal-Fetal Medicine's (SMFM) annual meeting, The Pregnancy Meeting™, researchers from the University of Pittsburgh will unveil findings that suggest that women who develop high blood pressure during pregnancy and who continue ...
2021-01-29
News reports indicate COVID-19 vaccines are not getting out soon enough nor in adequate supplies to most regions, but there may be a larger underlying problem than shortages. A University of California, Davis, study found that more than a third of people nationwide are either unlikely or at least hesitant to get a COVID-19 vaccine when it becomes available to them.
The results are from public polling of more than 800 English-speaking adults nationwide in a study published online earlier this month in the journal Vaccine.
"Our research indicates that vaccine uptake will be suboptimal ... with 14.8 percent of respondents being unlikely to get vaccinated ...
2021-01-29
WOODS HOLE, Mass. -- The most powerful substance in the human brain for neuronal communication is glutamate. It is by far the most abundant, and it's implicated in all kinds of operations. Among the most amazing is the slow restructuring of neural networks due to learning and memory acquisition, a process called synaptic plasticity. Glutamate is also of deep clinical interest: After stroke or brain injury and in neurodegenerative disease, glutamate can accumulate to toxic levels outside of neurons and damage or kill them.
Shigeki Watanabe of Johns Hopkins University School of Medicine, a familiar face at the Marine Biological Laboratory (MBL) as a faculty member and researcher, is hot on the ...
2021-01-29
RIVERSIDE, Calif. -- When we step on the car brake upon seeing a red traffic light ahead, a sequence of events unfolds in the brain at lightning speed.
The image of the traffic light is transferred from our eyes to the visual cortex, which, in turn, communicates to the premotor cortex -- a section of the brain involved in preparing and executing limb movements. A signal is then sent to our foot to step on the brake. However, brain region that helps the body go from "seeing" to "stepping" is still a mystery, frustrating neuroscientists and psychologists.
To unpack this "black box," a team of neuroscientists at the University of California, Riverside, has ...
2021-01-29
A new report combining forecasting and expert prediction data, predicts that 125,000 lives could be saved by the end of 2021 if 50% or more of the U.S. population initiated COVID vaccination by March 1, 2021.
"Meta and consensus forecast of COVID-19 targets," developed by Thomas McAndrew, a computational scientist and faculty member at Lehigh University's College of Health, and colleagues, incorporates data from experts and trained forecasters, combining their predictions into a single consensus forecast. In addition McAndrew and his team produce a metaforecast, which is a combination of an ensemble of computational models and their consensus forecast.
In addition to predictions related to the impact of vaccinations, ...
2021-01-29
Researchers at Linköping University, Sweden, have developed a proton trap that makes organic electronic ion pumps more precise when delivering drugs. The new technique may reduce drug side effects, and in the long term, ion pumps may help patients with symptoms of neurological diseases for which effective treatments are not available. The results have been published in Science Advances.
Approximately 6% of the world's population suffer from neurological diseases such as epilepsy, Parkinson's disease, and chronic pain. However, currently available drug delivery methods - mainly tablets and injections - place the drug in locations where it is not required. This can lead to side effects ...
2021-01-29
CAMBRIDGE, MA -- In many ways, our brain and our digestive tract are deeply connected. Feeling nervous may lead to physical pain in the stomach, while hunger signals from the gut make us feel irritable. Recent studies have even suggested that the bacteria living in our gut can influence some neurological diseases.
Modeling these complex interactions in animals such as mice is difficult to do, because their physiology is very different from humans'. To help researchers better understa nd the gut-brain axis, MIT researchers have developed an "organs-on-a-chip" system that replicates interactions between the brain, liver, and colon.
Using that system, the researchers were able to model the influence that microbes living in the gut have on both healthy brain tissue and tissue samples derived ...
LAST 30 PRESS RELEASES:
[Press-News.org] Adding ipilimumab to pembrolizumab does not improve efficacy in patients with NSCLC
Research presented today at the International Association for the Study of Lung Cancer's World Conference on Lung Cancer
